Selective estrogen receptor modulators (SERMs): A review of clinical data

被引:90
作者
Mirkin, Sebastian [1 ]
Pickar, James H. [2 ]
机构
[1] TherapeuticsMD, Boca Raton, FL USA
[2] Columbia Univ, Med Ctr, New York, NY USA
关键词
SERM; Menopause; Breast cancer; Osteoporosis; Endometrial cancer; SURGICAL ADJUVANT BREAST; POSTMENOPAUSAL WOMEN; BOWEL PROJECT; CARDIOVASCULAR EVENTS; ENDOMETRIAL CANCER; RISK REDUCTION; DOUBLE-BLIND; FOLLOW-UP; TAMOXIFEN; RALOXIFENE;
D O I
10.1016/j.maturitas.2014.10.010
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
030301 [社会学]; 100201 [内科学];
摘要
SERMs represent a diverse group of molecules with varying levels of estrogenic agonist and antagonist activity in target tissues. SERMs have a long regulatory approval history and have been studied for a variety of therapeutic indications. The clinical effects of SERMs have been evaluated in a large number of phase 3 clinical trials. Many of the available SERMs have proved to be effective as chemo-preventive agents and treatments for breast cancer and a number are useful for the prevention and treatment of osteoporosis. The endometrial effect of SERMs has been a key differentiator in clinical practice and a major hurdle for regulatory approval. The effect of SERMs in the vagina also represents a major distinction among different SERMs. This review summarized key clinical finding of SERMs in different target tissues. (C) 2014 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:52 / 57
页数:6
相关论文
共 57 条
[1]
Abe O, 2005, LANCET, V366, P2087, DOI 10.1016/s0140-6736(05)66544-0
[2]
[Anonymous], 2012, FAR PACK INS
[3]
[Anonymous], 2005, NOLV PACK INS
[4]
Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women [J].
Archer, David F. ;
Pinkerton, JoAnn V. ;
Utian, Wulf H. ;
Menegoci, Jose C. ;
de Villiers, Tobie J. ;
Yuen, Chui Kin ;
Levine, Amy B. ;
Chines, Arkadi A. ;
Constantine, Ginger D. .
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2009, 16 (06) :1109-1115
[5]
Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women [J].
Barrett-Connor, Elizabeth ;
Mosca, Lori ;
Collins, Peter ;
Geiger, Mary Jane ;
Grady, Deborah ;
Kornitzer, Marcel ;
McNabb, Michelle A. ;
Wenger, Nanette K. .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (02) :125-137
[6]
Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial [J].
Cauley, JA ;
Norton, L ;
Lippman, ME ;
Eckert, S ;
Krueger, KA ;
Purdie, DW ;
Farrerons, J ;
Karasik, A ;
Mellstrom, D ;
Ng, KW ;
Stepan, JJ ;
Powles, TJ ;
Morrow, M ;
Costa, A ;
Silfen, SL ;
Walls, EL ;
Schmitt, H ;
Muchmore, DB ;
Jordan, VC .
BREAST CANCER RESEARCH AND TREATMENT, 2001, 65 (02) :125-134
[7]
Constantine GD, 2014, MENOPAUSE
[8]
The effect of raloxifene on risk of breast cancer in postmenopausal women - Results from the MORE randomized trial [J].
Cummings, SR ;
Eckert, S ;
Krueger, KA ;
Grady, D ;
Powles, TJ ;
Cauley, JA ;
Norton, L ;
Nickelsen, T ;
Bjarnason, NH ;
Morrow, M ;
Lippman, ME ;
Black, D ;
Glusman, JE ;
Costa, A ;
Jordan, VC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (23) :2189-2197
[9]
Arzoxifene for Prevention of Fractures and Invasive Breast Cancer in Postmenopausal Women [J].
Cummings, Steven R. ;
McClung, Michael ;
Reginster, Jean-Yves ;
Cox, David ;
Mitlak, Bruce ;
Stock, John ;
Amewou-Atisso, Messan ;
Powles, Trevor ;
Miller, Paul ;
Zanchetta, Jose ;
Christiansen, Claus .
JOURNAL OF BONE AND MINERAL RESEARCH, 2011, 26 (02) :397-404
[10]
Lasofoxifene in Postmenopausal Women with Osteoporosis [J].
Cummings, Steven R. ;
Ensrud, Kristine ;
Delmas, Pierre D. ;
LaCroix, Andrea Z. ;
Vukicevic, Slobodan ;
Reid, David M. ;
Goldstein, Steven ;
Sriram, Usha ;
Lee, Andy ;
Thompson, John ;
Armstrong, Roisin A. ;
Thompson, David D. ;
Powles, Trevor ;
Zanchetta, Jose ;
Kendler, David ;
Neven, Patrick ;
Eastell, Richard .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (08) :686-696